LON:SARSareum Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sareum Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 0.71 -0.06 (-7.79 %) (As of 05/29/2020 11:07 AM ET) Add Compare Share Today's Range 0.70Now: GBX 0.71▼ 0.7750-Day Range 0.34MA: GBX 0.67▼ 0.8752-Week Range 0.03Now: GBX 0.71▼ 1.10Volume9.00 million shsAverage Volume6.23 million shsMarket Capitalization£21.81 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Sareum Holdings plc engages in the discovery and development of therapeutic drugs to treat cancer and autoimmune diseases. It develops therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Sareum. Previous Next 2.4 Community Rank Outperform VotesSareum has received 79 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSareum has received 83 “underperform” votes. (Add your “underperform” vote.)Community SentimentSareum has received 51.23% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sareum and other stocks. Vote “Outperform” if you believe SAR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SAR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSareum does not currently pay a dividend.Dividend GrowthSareum does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sareum insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sareum is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sareum is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:SAR Previous Symbol CUSIPN/A CIKN/A Webwww.sareum.co.uk Phone+44-1223-497700Debt Debt-to-Equity RatioN/A Current Ratio8.46 Quick Ratio8.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares3,071,360,000Market Cap£21.81 million Next Earnings DateN/A OptionableNot Optionable LSE:SAR Rates by TradingView Receive SAR News and Ratings via Email Sign-up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter. Sareum (LON:SAR) Frequently Asked Questions How has Sareum's stock been impacted by COVID-19 (Coronavirus)? Sareum's stock was trading at GBX 0.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAR stock has increased by 132.8% and is now trading at GBX 0.71. View which stocks have been most impacted by Coronavirus. Has Sareum been receiving favorable news coverage? Media coverage about SAR stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sareum earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutSareum. Who are some of Sareum's key competitors? Some companies that are related to Sareum include Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), NanoViricides (NNVC), Vita Life Sciences (VLS), Pharmaxis (PXS), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Patrys (PAB), Cathay International (CTI), N4 Pharma (N4P), Bayer (BAYN) and HedgePath Pharmaceuticals (MAYNF). View all competitors. What other stocks do shareholders of Sareum own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Collagen Solutions (COS), Gulf Keystone Petroleum (GKP), Egdon Resources (EDR), Madagascar Oil (MOIL), Rockhopper Exploration (RKH), Anglo Pacific Group (APF) and Avesoro Resources (ASO). Who are Sareum's key executives? Sareum's management team includes the following people: Dr. Tim J. Mitchell, Founder, CEO & Exec. Director (Age 59)Dr. John C. Reader Ph.D., Founder, Chief Scientific Officer & Exec. Director (Age 52)Tony Bunn FCMA, Sec. What is Sareum's stock symbol? Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR." How do I buy shares of Sareum? Shares of SAR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Sareum's stock price today? One share of SAR stock can currently be purchased for approximately GBX 0.71. How big of a company is Sareum? Sareum has a market capitalization of £21.81 million. What is Sareum's official website? The official website for Sareum is www.sareum.co.uk. How can I contact Sareum? Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The company can be reached via phone at +44-1223-497700. This page was last updated on 5/29/2020 by MarketBeat.com Staff
